SecBot SecBot
8-K ·Filed Feb 26, 2026

LGND

LIGAND PHARMACEUTICALS INC
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0000886163-26-000003
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong results and reaffirmed guidance suggest continued momentum in Ligand's royalty portfolio. Traders should monitor upcoming catalysts from partner programs including Filspari, Ohtuvayre, and Tzield, which could provide additional upside.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$196.17
T+0 close · Feb 26, 2026 · via day close
Latest settled
+13.26%
T+60 · $222.18
Vs SPY
+5.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $196.17entry
  2. T+1 · 9mo ago +1.09%α +1.54% · $198.31
  3. T+5 · 9mo ago +5.15%α +6.28% · $206.27
  4. T+20 · 8mo ago +3.84%α +10.24% · $203.70
  5. T+60 · 6mo ago +13.26%α +5.51% · $222.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ligand Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, driven by a 48% increase in royalty revenue. The company achieved GAAP net income of $124.5 million and core adjusted EPS of $8.13, exceeding prior guidance. Ligand is reaffirming its 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS.

Key Financial Metrics

Revenue
$268.1M
+60.4% YoY
Adj. EPS
$8.13
GAAP: $6.13
Guidance
$245-$285 million
maintained

Key Facts

  • Full year 2025 revenue was $268.1 million, up from $167.1 million in 2024, driven by 48% growth in royalty revenue to $161.0 million
  • Core adjusted EPS was $8.13 for 2025, exceeding initial guidance by approximately 30%
  • GAAP net income was $124.5 million, a significant improvement from a $4.0 million net loss in 2024
  • Company reaffirmed 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS
  • Cash, cash equivalents, and short-term investments totaled $733.5 million as of December 31, 2025

Financial Impact

Revenue increased 60.4% year-over-year to $268.1 million, with core adjusted net income growing 52.2% to $165.1 million

revenueepsnet incomecash position

Segment Breakdown

SegmentRevenueGrowth
Royalties$161.0M+48.0%
Captisol$40.2M+30.1%
Contract revenue and income$66.9M+143.7%

Risk Factors

  • Future performance depends on partner drug development and commercialization success
  • The $28.6 million gain from the Pelthos sale was a one-time item and not indicative of recurring performance
  • Company faces risks related to partner program discontinuations and impairments

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000886163-26-000003
Document: lgnd-20260226.htm0000886163-26-000003
Document: 0000886163-26-000003-index-headers.html0000886163-26-000003
Document: 0000886163-26-000003-index.html0000886163-26-000003
Document: 0000886163-26-000003.txt0000886163-26-000003

US Market Status

Market Closed · Opens in 7h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026